Google
ZNTL — ZENTALIS PHARMACEUTICALS LLC (Healthcare >> Biotechnology)
ZNTL FAQ
What is ZNTL's ROE?
ZENTALIS PHARMACEUTICALS LLC reports a Return on Equity (ROE) of -67.95%.
What is ZNTL's dividend yield?
ZENTALIS PHARMACEUTICALS LLC offers a dividend yield of 0.00%.
What is ZNTL's Deepscope Quality Score?
Deepscope rates ZNTL's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ZNTL?
Deepscope's AI Timing Score for ZNTL is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ZNTL belong to?
ZENTALIS PHARMACEUTICALS LLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 3.58
Price
0.00
(0.00%)
Day Change
|
|
|---|
ZNTL, the overall quality is not good ( Quality = 8) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 46 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.58 |
| PBV / Sector |
1.43 / 4.71
GOOD
|
| Earning Per Share | -1.71 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
3.75 M
GREAT
|
| Average 1W Daily Value |
2.70 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-10 09:43:17 |
| Symbol | ZNTL |
| Name | ZENTALIS PHARMACEUTICALS LLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 71.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 260.54 / 8,889.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10275 Science Center Dr., San Diego, CA, United States, 92121
Phone: 858 263 4333
Website: https://zentalis.com
Employees: 106
Sector: Healthcare >> Biotechnology
Description: Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
